Adjunctive Treatment with Interferon Alpha 2b in Conjunctival Melanoma.

IF 0.9 Q4 OPHTHALMOLOGY

Ocular Oncology and Pathology Pub Date : 2022-06-01 Epub Date: 2022-01-27 DOI:10.1159/000522195

Valentín Huerva, Pau Cid-Bertomeu, Ramón Espinet, Luisa M Canto

{"title":"Adjunctive Treatment with Interferon Alpha 2b in Conjunctival Melanoma.","authors":"Valentín Huerva, Pau Cid-Bertomeu, Ramón Espinet, Luisa M Canto","doi":"10.1159/000522195","DOIUrl":null,"url":null,"abstract":"Purpose: The aim of the study was to demonstrate the clinical outcomes after resection of conjunctival melanoma (CM) followed by topical interferon (IFN) alpha 2b after a long follow-up.Methods: Two consecutive CM patients were treated using tumor excision followed by topical IFN alpha 2b (1,000,000 UI/mL) four times a day for 12 weeks. The second case presented positivity due to the presence of tumor cells in the lower margin of the resection. TNM staging was T1c, N0b, M0, and T1b in the first case and T1b, N0b, M0 in the second case. Follow-up was 72 and 71 months, respectively.Results: No side effects were observable after the administration of topical IFN alpha 2b. After extensive evaluation and imaging with computed tomography, no regrowth or distant metastasis was noticed during the follow-up period in both cases.Conclusions: IFN alpha 2b could be used as a co-adjuvant treatment after CM resection, in an attempt to reduce the possibility of recurrences.","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218643/pdf/oop-0008-0088.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ocular Oncology and Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000522195","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/27 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The aim of the study was to demonstrate the clinical outcomes after resection of conjunctival melanoma (CM) followed by topical interferon (IFN) alpha 2b after a long follow-up.

Methods: Two consecutive CM patients were treated using tumor excision followed by topical IFN alpha 2b (1,000,000 UI/mL) four times a day for 12 weeks. The second case presented positivity due to the presence of tumor cells in the lower margin of the resection. TNM staging was T1c, N0b, M0, and T1b in the first case and T1b, N0b, M0 in the second case. Follow-up was 72 and 71 months, respectively.

Results: No side effects were observable after the administration of topical IFN alpha 2b. After extensive evaluation and imaging with computed tomography, no regrowth or distant metastasis was noticed during the follow-up period in both cases.

Conclusions: IFN alpha 2b could be used as a co-adjuvant treatment after CM resection, in an attempt to reduce the possibility of recurrences.

Abstract Image

查看原文本刊更多论文

结膜黑色素瘤的 Alpha 2b 干扰素辅助治疗。

目的：该研究旨在证明结膜黑色素瘤（CM）切除术后，经过长期随访后局部使用干扰素（IFN）α 2b 的临床疗效：连续对两名结膜黑色素瘤患者进行了肿瘤切除治疗，然后外用 IFN alpha 2b （1,000,000 UI/mL），每天四次，持续 12 周。第二个病例由于切除下缘存在肿瘤细胞而出现阳性反应。第一个病例的TNM分期为T1c、N0b、M0和T1b，第二个病例的TNM分期为T1b、N0b、M0。随访时间分别为 72 个月和 71 个月：局部使用 IFN alpha 2b 后未发现副作用。经过广泛评估和计算机断层扫描成像，两例患者在随访期间均未发现再生或远处转移：结论：IFN α 2b 可作为肿瘤切除术后的辅助治疗，以减少复发的可能性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ocular Oncology and Pathology OPHTHALMOLOGY-

CiteScore

2.40

自引率

0.00%

发文量